Hydrocortison Hualan (Hydrocortisone)

Hydrocortison Hualan is indicated for several clinical situations where glucocorticoid activity is required.

• Treatment of primary or secondary adrenal insufficiency (Addison's disease).
• Management of acute inflammatory disorders such as severe asthma exacerbations.
• Relief of moderate to severe allergic reactions, including skin and systemic manifestations.
• Adjunct therapy for certain rheumatic conditions where inflammation control is needed.
• Short‑term use in postoperative or traumatic settings to reduce inflammatory response.
• Temporary control of endocrine symptoms during diagnostic testing for cortisol deficiency.
• Supportive therapy in certain dermatologic conditions where systemic anti‑inflammatory effect is required.

• Hydrocortison Hualan delivers hydrocortisone, which binds to intracellular glucocorticoid receptors. The drug‑receptor complex translocates to the nucleus and interacts with glucocorticoid response elements, modulating gene transcription. This results in decreased production of pro‑inflammatory cytokines, prostaglandins, and leukotrienes, and suppresses immune cell activation. The overall effect is a reduction in inflammation and replacement of deficient endogenous cortisol. It also influences carbohydrate, protein and lipid metabolism, contributing to its systemic effects.

Like other systemic glucocorticoids, Hydrocortison Hualan may be associated with a range of adverse reactions, which vary in frequency and severity.

Common

• Increased appetite or weight gain.
• Fluid retention leading to mild edema.
• Elevated blood glucose levels, especially in predisposed individuals.
• Mood changes such as irritability or mild anxiety.
• Gastrointestinal discomfort, including dyspepsia or nausea.
• Skin thinning or easy bruising.

Serious

• Severe hyperglycemia or new‑onset diabetes mellitus.
• Significant hypertension or worsening of existing cardiovascular disease.
• Suppression of the hypothalamic‑pituitary‑adrenal (HPA) axis.
• Opportunistic infections due to immune suppression.
• Osteoporosis or increased risk of fractures with prolonged use.
• Psychiatric disturbances such as severe depression or psychosis.

Before initiating Hydrocortison Hualan, clinicians should evaluate several patient‑specific factors to minimize risk and ensure appropriate use.

• Assess adrenal function to confirm the need for glucocorticoid replacement.
• Review history of hypertension, diabetes, or cardiovascular disease, as glucocorticoids may exacerbate these conditions.
• Evaluate for active infections; avoid use in uncontrolled bacterial, viral, or fungal infections.
• Consider bone health status, especially in patients at risk for osteoporosis.
• Use the lowest effective dose for the shortest duration required.

Hydrocortison Hualan can affect the pharmacokinetics or pharmacodynamics of several other medicines; awareness of these interactions helps prevent adverse outcomes.

Avoid

• Concurrent use with strong CYP3A4 inducers (e.g., rifampin, phenytoin) which may reduce hydrocortisone plasma levels.
• Co‑administration with potent immunosuppressants such as cyclosporine without dose adjustment, increasing risk of infection.
• Simultaneous use of non‑steroidal anti‑inflammatory drugs (NSAIDs) in high doses, which may raise the chance of gastrointestinal bleeding.

Use with caution

• Antidiabetic agents, as glucocorticoids can raise blood glucose and may require dose changes.
• Antihypertensive medications, because fluid retention may blunt their effectiveness.
• Vaccines, particularly live attenuated vaccines, due to possible reduced immune response.
• Anticoagulants, since glucocorticoids may affect coagulation parameters.